ANTI-DUMPING / INITIATION

DGTR opens anti-dumping investigation into amoxycillin trihydrate from China

DGTR's notice of September 24, 2026 opens an anti-dumping investigation into amoxycillin trihydrate from China, covering April 2025 to March 2026.

THE DIRECTORATE General of Trade Remedies has initiated an anti-dumping investigation, by notification dated September 24, 2026 (SETU Case ID – AD/OI/060/2026), concerning imports of Amoxycillin Trihydrate originating in or exported from China.

KEY FACTS

MEASURE
Anti-dumping

STAGE
Initiation

COUNTRIES
China

DATED
September 24, 2026

REFERENCES

SETU Case ID – AD/OI/060/2026

F. No. 6/59/2026-DGTR

CG-DL-E-02102026-276715

HS CODES 1

29411030

DGTR opens anti-dumping investigation into amoxycillin trihydrate from China

SETU Case ID – AD/OI/060/2026 · Initiation · September 24, 2026

The Directorate General of Trade Remedies has initiated an anti-dumping investigation, by notification dated September 24, 2026 (SETU Case ID – AD/OI/060/2026), concerning imports of Amoxycillin Trihydrate originating in or exported from China.

The application was filed by Apitoria Pharma Private Limited, a stepdown wholly owned subsidiary of Aurobindo Pharma Ltd., and is supported by Centrient Pharmaceuticals India Private Limited. The applicant states it accounts for more than 35% of Indian production, and the two together for more than 60%. Amoxicillin is described as a broad-spectrum penicillin antibiotic. The product is classified under sub-heading 29411030, which is indicative only.

The period of investigation is April 1, 2025 to March 31, 2026, and the injury period covers the three financial years from April 1, 2022 to March 31, 2025 and the period of investigation. Normal value for China was constructed from the applicant's cost of production. The Authority finds prima facie evidence of a dumping margin above de minimis, an absolute increase in subject imports and an adverse effect on the domestic industry's profitability.

Interested parties must register on the SETU portal and file questionnaire responses within 37 days from circulation of the non-confidential version of the application. Comments on the product scope and PCN methodology are due within 15 days, running concurrently. The Authority will determine the existence, degree and effect of dumping and recommend any duty needed to remove injury.

Measure	Anti-dumping
Stage	Initiation
Case number	SETU Case ID – AD/OI/060/2026
File number	F. No. 6/59/2026-DGTR
Dated	September 24, 2026
Published in the Gazette	September 24, 2026
Put online	October 2, 2026
Gazette ID	CG-DL-E-02102026-276715
Product	Amoxycillin Trihydrate
What it covers	Amoxicillin is a semi-synthetic, broad-spectrum penicillin antibiotic used mainly to treat bacterial infections of the respiratory tract, ear,

	throat, urinary tract and skin, and dental infections, and in combination with other drugs for H. pylori-related peptic ulcers. The unit of measurement is Metric Tonnes (MT), and the customs classification is indicative only and not binding on the scope.
Customs codes	29411030
Countries	China
Applicant	Apitoria Pharma Private Limited, supported by Centrient Pharmaceuticals India Private Limited
Period of investigation	1st April 2025 to 31st March 2026 (12 months)
Injury period	1st April 2022 to 31st March 2023, 1st April 2023 to 31st March 2024, 1st April 2024 to 31st March 2025 and the period of investigation
Findings	• The applicant, a stepdown wholly owned subsidiary of Aurobindo Pharma Ltd., states it accounts for more than 35% of Indian production, and with the supporter for more than 60%; the Authority considers it an eligible domestic industry under Rule 2(b) and finds Rule 5(3) satisfied. • The applicant claims China should be treated as a non-market economy; normal value was constructed on the applicant's cost of production, adjusted for selling, general and administrative expenses, with reasonable profit. • A comparison of normal value and export price at ex-factory level prima facie shows a dumping margin above the de-minimis level. • The volume of subject imports has increased in absolute terms and the imports have had an adverse impact on the profitability parameters of the domestic industry. • The Authority prima facie finds sufficient evidence of dumping, injury and causal link to justify initiation under Rule 5.
Recommendation	The Authority initiates an anti-dumping investigation under Section 9A of the Act read with Rule 5 to determine the existence, degree and effect of dumping and to recommend an appropriate amount of anti-dumping duty adequate to remove the injury to the domestic industry.
Time limits	• Comments on the scope of the product under consideration and proposed PCN methodology: within 15 days of circulation of the receipt of intimation of initiation of the investigation, running concurrently with the time limit for submissions • Questionnaire responses and other submissions, confidential and non-confidential versions, on the SETU portal (case ID AD/OI/060/2026): within 37 days from the date on which the non-confidential version of the application is circulated by the Authority

or transmitted to the diplomatic representative of the exporting country
- Requests for extension of time: at least one day before the original deadline
- Comments on issues of confidentiality: within 7 days from the date of circulation of the non-confidential version of the documents

The notification (PDF, 811 KB)

Gazette of India, CG-DL-E-02102026-276715, published September 24, 2026.

Checked against the official copy on October 20, 2026.

IndusDesk

hello@indusdesk.com · +91 11 4141 3939

9th Floor, Hemkunt House, Rajendra Place, New Delhi, Delhi 110008, India

Read online: indusdesk.com/dgtr/tracker/opens-anti-dumping-investigation-into-amoxycillin-trihydrate-276715/